Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia

Journal of Neuroimmunology

Volumn 221, Issue 1-2, 2010, Pages 101-106

  Shiao, Yu Ming ^a,b   Lee, Chin Cheng ^c,d,e   Hsu, Yung Hsiang ^f   Huang, Shiu Feng ^b   Lin, Chung Yen ^g   Li, Ling Hui ^h   Fann, Cathy S J ^h   Tsai, Chang Youh ⁱ   Tsai, Shih Feng ^a,b   Chiu, Hou Chang ^c,d,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f Buddhist Tzu Chi General Hospital and University   (Taiwan)

^g INSTITUTE OF INFORMATION SCIENCE   (Taiwan)

^h INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

ⁱ TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Chemokine; CXCL13; Gene expression microarray; Myasthenia gravis

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; CYTOKINE ANTIBODY; MESSENGER RNA; PREDNISOLONE; CXCR5 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNITY; CELL MIGRATION; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; LYMPHOID HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; THYMECTOMY; THYMUS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SEX DIFFERENCE; THYMUS HYPERPLASIA;

ADULT; AGED; AGED, 80 AND OVER; CHEMOKINE CXCL13; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CXCR5; RNA, MESSENGER; SEX FACTORS; THYMUS GLAND; THYMUS HYPERPLASIA; YOUNG ADULT;

EID: 77951228240     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.02.013     Document Type: Article

References (33)

1. Ansel K.M., Ngo V.N., Hyman P.L., Luther S.A., Förster R., Sedgwick J.D., Browning J.L., Lipp M., Cyster J.G. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000, 406:309-314.
2. Ansel K.M., Harris R.B., Cyster J.G. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 2002, 16:67-76.
3. Barone F., Bombardieri M., Manzo A., Blades M.C., Morgan P.R., Challacombe S.J., Valesini G., Pitzalis C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum. 2005, 52:1773-1784.
4. Buckingham J.M., Howard F.M., Bernatz P.E., Payne W.S., Harrison E.G., O'Brien P.C., Weiland L.H. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann. Surg. 1976, 184:453-458.
5. Carlsen H.S., Baekkevold E.S., Morton H.C., Haraldsen G., Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood 2004, 104:3021-3027.
6. Dauphinée M., Tovar Z., Talal N. B cells expressing CD5 are increased in Sjögren's syndrome. Arthritis Rheum. 1988, 31:642-647.
7. Drachman D.B. Myasthenia gravis. New Engl. J. Med. 1994, 330:1797-1810.
8. Feferman T., Maiti P.K., Berrih-Aknin S., Bismuth J., Bidault J., Fuchs S., Souroujon M.C. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J. Immunol. 2005, 174:5324-5331.
9. Förster R., Mattis A.E., Kremmer E., Wolf E., Brem G., Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of spleen. Cell 1996, 87:1037-1047.
10. Gronseth G.S., Barohn R.J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of Quality Standards Subcommittee of American Academy of Neurology. Neurology 2000, 55:7-15.
11. Gunn M.D., Ngo V.N., Ansel K.M., Ekland E.H., Cyster J.G., Williams L.T. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 1998, 391:799-803.
12. Hardy R.R., Hayakawa K. B cell developmental pathways. Annu. Rev. Immunol. 2001, 19:595-621.
13. Hayakawa K., Hardy R.R. Development and function of B-1 cells. Curr. Opin. Immunol. 2000, 12:346-353.
14. Hayakawa K., Hardy R.R., Parks D.R., Herzenberg L.A. The "Ly-1 B" cell subpopulations in normal, immunodefective, and autoimmune mice. J. Exp. Med. 1983, 157:202-218.
15. Hohlfeld R., Wekerle H. The role of the thymus in myasthenia gravis. Adv. Neuroimmunol. 1994, 4:373-386.
16. + dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J. Exp. Med. 2001, 193:1393-1402.
17. Ito T., Ishikawa S., Sato T., Akadegawa K., Yurino H., Kitabatake M., Hontsu S., Ezaki T., Kimura H., Matsushima K. Defective B1 cell homing to the peritoneal cavity and preferential recruitment of B1 cells in the target organs in a murine model for systemic lupus erythematosus. J. Immunol. 2004, 172:3628-3634.
18. Kurtzke J.F., Kurland L.T. Chapter 66: the epidemiology of neurologic disease. Clinical Neurology 1992, vol. 4. J.B. Lippincott, Philadelphia, 80-8. Rev. ed. R.J. Joynt (Ed.).
19. Le Panse R., Cizeron-Clairac G., Bismuth J., Berrih-Aknin S. Microarrays reveal distinct gene signatures in thymus of seropositive and seronegative myasthenia gravis patients and the roles of CC chemokine ligand 21 in thymic hyperplasia. J. Immunol. 2006, 177:7868-7869.
20. Meraouna A., Cizeron-Clairac G., Panse R.L., Bismuth J., Truffault F., Tallaksen C., Berrih-Aknin S. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006, 108:432-440.
21. Ngo V.N., Korner H., Gunn M.D., Schmidt K.N., Riminton D.S., Cooper M.D., Browning J.L., Sedgwick J.D., Cyster J.G. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 1999, 189:403-412.
22. Onodera H. The role of thymus in the pathogenesis of myasthenia gravis. Tohoku J. Exp. Med. 2005, 207:87-98.
23. Pan Q., Kravchenko V., Katz A., Huang S., Ii M., Mathison J.C., Kobayashi K., Flavell R.A., Schreiber R.D., Goeddel D., Ulevitch R.J. NF-kappa B-inducing kinase regulates selected gene expression in the Nod2 signaling pathway. Infect. Immun. 2006, 74:2121-2127.
24. Papatestas A.E., Alpert L.I., Osserman K.E., Osserman R.S., Kark A.E. Studies in myasthenia gravis: effects of thymectomy: results on 185 patients with nonthymomatous and thymomatous myasthenia gravis, 1941-1969. Am. J. Med. 1971, 50:465-474.
25. Plater-Zyberk C., Maini R.N., Lam K., Kennedy T.D., Janossy G. A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum. 1985, 28:971-976.
26. Poussin M.A., Goluszko E., Hughes T.K., Duchicella S.I., Christadoss P. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J. Neuroimmunol. 2000, 111:152-160.
27. Roy M.P., Kim C.H., Butcher E.C. Cytokine control of memory B cell homing machinery. J. Immunol. 2002, 169:1676-1682.
28. Saito R., Onodera H., Tago H., Suzuki Y., Shimizu M., Matsumura Y., Kondo T., Itoyama Y. Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients. J. Neuroimmunol. 2005, 170:172-178.
29. Sato T., Ishikawa S., Akadegawa K., Ito T., Yurino H., Kitabatake M., Yoneyama H., Matsushima K. Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur. J. Immunol. 2004, 34:3346-3358.
30. Shi K., Hayashida K., Kaneko M., Hashimoto J., Tomita T., Lipsky P.E., Yoshikawa H., Ochi T. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J. Immunol. 2001, 166:650-655.
31. Tüzün E., Meriggioli M.N., Rowin J., Yang H., Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment. J. Autoimmun. 2005, 24:261-268.
32. Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet 2001, 357:2122-2128.
33. Yoshikawa H., Sato K., Edahiro S., Furukawa Y., Maruta T., Iwasa K., Watanabe H., Takaoka S., Suzuki Y., Takamori M., Yamada M. Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma. J. Neuroimmunol. 2006, 175:169-175.